Brand and Other Names:Fortaz, Tazicef, more...Tazidime
- Classes: Cephalosporins, 3rd Generation
Dosing & Uses
Dosage Forms & Strengths
powder for injection
Bone & Joint Infections
2 g IV q12hr
Gynecologic & Intra-abdominal Infections
2 g IV q8hr for 4-7 days
Infections caused by Pseudomonas spp in patients with cystic fibrosis who have healthy renal function
2 g IV q8hr
Uncomplicated: 0.5-1 g IV q8hr
Complicated: 2 g IV q8hr
Mild Skin/Skin Structure Infections
0.5-1 g IV or IM q8hr
Urinary Tract Infections
Complicated: 500 mg IV or IM q8-12hr
Uncomplicated: 250 mg IV or IM q12hr
Especially in immunocompromised patients
2 g IV q8hr
- Modifications based on 1-g dose
- CrCl 31-50 mL/min: 1 g q12hr
- CrCl 16-30 mL/min: 1 g q24hr
- CrCl 6-15 mL/min: 500 mg q24hr
- CrCl <5 mL/min: 500 mg q48hr
- Citrobacter spp, Clostridium spp, Enterobacter spp, Escherichia coli, Haemophilus influenzae, Klebsiella spp, Moraxella catarrhalis, Neisseria meningitidis, Proteus mirabilis, Pseudomonas spp, Serratia spp, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes
Dosage Forms & Strengths
powder for injection
Infections Caused by Susceptible Organisms
<1 month: Safety and efficacy not established
>12 years: 1-2 g IV q8hr
Use sodium carbonate preparation
Usual dosing range for neonates (per American Academy of Pediatrics)
- 7-28 days: 50 mg/kg IV q8hr
- <7 days, <2 kg: 50 mg/kg IV q12hr
- <7 days, >2 kg: 50 mg/kg IV q8-12hr
Serious - Use Alternative
Significant - Monitor Closely
Transient increases in transaminases (3-9%)
Immune hypersensitivity reaction (2%)
Rash (maculopapular or erythematous) (2%)
Injection site pain (1%)
Increased serum concentrations of bilirubin
Nausea or vomiting
Transient increases in blood urea nitrogen (BUN) or serum creatinine
Documented hypersensitivity to drug or components
High serum concentrations may result in serious adverse nervous system effects
Elevated international normalized ratio (INR) has reported in patients with nutritional deficiency, prolonged treatment, or renal or hepatic disease
Use with caution in patients with history of seizure disorder (especially in renal impairment, where drug levels may increase significantly)
Modify dose in renal impairment
Use with caution in patients with history of penicillin allergy
Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy
Pregnancy & Lactation
Pregnancy category: B
Lactation: Drug excreted in breast milk; use with caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Third-generation cephalosporin with broad-spectrum gram-negative activity, including Pseudomonas; has lower efficacy against gram-positive organisms and higher efficacy against resistant organisms; arrests bacterial growth by binding to 1 or more penicillin-binding proteins, thereby, in turn, inhibiting final transpeptidation step of peptidoglycan synthesis in bacterial cell-wall synthesis and inhibiting cell-wall biosynthesis
Peak plasma time: IM, 1 hr
Widely distributed to body tissues and fluids, including aqueous humor, ascitic and prostatic fluids, and bone; penetrates CSF when meninges are inflamed
Protein bound: 5-24%
Half-life: 1-2 hr
Dialyzable: Hemodialysis, yes; peritoneal dialysis, yes
Excretion: Urine (80-90% as unchanged drug)
Additive: Amikacin, aminophylline, ciprofloxacin, gentamicin, ranitidine
Y-site: Amiodarone, amphotericin B cholesteryl complex, azithromycin, amsacrine, clarithromycin, cisatracurium(?), doxorubicin liposome, erythromycin lactobionate, fluconazole(?), idarubucin, midazolam, nicardipine (incompatible at ceftazidime 125 mg/mL but compatible at ceftazidime 10 mg/mL), pentamidine, propofol (incompatible at ceftazidime 125 mg/mL but compatible at ceftazidime 40 mg/mL), sagramostim(?), vancomycin(?), warfarin
- Direct injection: Inject over 3-5 minutes directly into vein or through tubing of running compatible infusion solution
- Infusion: Infuse intermittently over 15-30 minutes
- Inject deeply
Store intact vials at room temperature, protected from light
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs